

Christian Britschgi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1835703/publications.pdf>

Version: 2024-02-01

21
papers

528
citations

1040056

9
h-index

839539

18
g-index

24
all docs

24
docs citations

24
times ranked

752
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880. | 1.6 | 183 |
| 2 | Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100. | 7.1 | 68 |
| 3 | Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2022, 28, 1117-1126. | 7.0 | 52 |
| 4 | Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2018, 13, 102. | 2.7 | 44 |
| 5 | Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 6345-6354. | 7.0 | 43 |
| 6 | SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016. | 1.6 | 27 |
| 7 | Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154. | 5.9 | 23 |
| 8 | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1299. | 2.8 | 20 |
| 9 | The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. <i>Immunobiology</i> , 2020, 225, 152009. | 1.9 | 18 |
| 10 | Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1082-1087. | 3.0 | 9 |
| 11 | Severe reaction to radiotherapy provoked by hypomorphic germline mutations in <i>ATM</i> (ataxia-telangiectasia mutated gene). <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1409. | 1.2 | 8 |
| 12 | Genome-wide non-invasive prenatal testing in single- and multiple-pregnancies at any risk: Identification of maternal polymorphisms to reduce the number of unnecessary invasive confirmation testing. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 19-29. | 1.1 | 7 |
| 13 | When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma. <i>Life</i> , 2021, 11, 869. | 2.4 | 7 |
| 14 | Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1605-1613. | 4.2 | 6 |
| 15 | Safety of Tepotinib in Patients With <i>MET</i> Exon 14 Skipping NSCLC and Recommendations for Management. <i>Clinical Lung Cancer</i> , 2022, 23, 320-332. | 2.6 | 5 |
| 16 | Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. <i>Sarcoma</i> , 2021, 2021, 1-12. | 1.3 | 4 |
| 17 | Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 75. | 3.7 | 3 |
| 18 | Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue—A pilot study. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104705. | 2.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | What's new in chemotherapy for non-small cell lung cancer?. Memo - Magazine of European Medical Oncology, 2017, 10, 123-126. | 0.5 | 0 |
| 20 | Establishment of a tissue microarray (TMA) platform as an efficient tool for soft tissue sarcoma (STS) research available for collaboration.. Journal of Global Oncology, 2019, 5, 38-38. | 0.5 | 0 |
| 21 | Frequency, molecular characteristics, and therapeutic targeting of ROS1 oncogenic fusions in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 160-160. | 1.6 | 0 |